An Exploratory, Prospective, Open-label, Randomized, Three-arm, Single-centre, Safety, Efficacy and In-use Tolerability Study of the Three Different Test Products in Healthy Adult Human Subjects With Dry and Sensitive Skin.
Sponsor study identifier
interventional
84
1 country
1
Study Start
December 7, 2024
Actual (reported)Primary Completion
February 18, 2025
Actual (reported)Study Completion
February 18, 2025
Actual (reported)An exploratory, prospective, open-label, randomized, three-arm, single-centre, safety, efficacy and in-use tolerability study of the three different test products in healthy adult human subjects with dry and sensitive skin. This exploratory, prospective, open-label, randomized, three-arm, single-centre, safety, efficacy and in-use tolerability study of the three different test products in healthy adult human subjects with dry and sensitive skin.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 18, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 6, 2024
Actual (reported)November 7, 2024
Actual (reported)December 7, 2024
Actual (reported)February 18, 2025
Actual (reported)February 18, 2025
Actual (reported)To evaluate the effectiveness of the test products in terms of change in skin hydration
Instrumental evaluation by Corneometer CM 825
before usage of the test product on Day 01 and after usage of the test product at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in DASI score
Using DASI Score where 0 is absent 4 is extreme
before usage of the test product on Day 01 and after usage of the test product at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in overall dry skin score (ODS)
Using scoring scale where 0 is absent and 4 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in PGA score
Scoring scale where 0 is none and 8 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of test products in terms of change in skin barrier function
Instrumental Evaluation by Tewameter TM Hex
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in skin roughness
Using Scoring Scale 0 is absent and 4 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in skin scaliness
Using Scoring Scale 0 is absent and 4 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in skin smoothness
Using Scoring Scale 0 is absent and 4 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in skin wrinkles
Using Scoring Scale 0 is absent and 4 is extreme
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test product in terms of change in desquamation index
before usage of the test products on Day 01 and after usage of the test products at T20 mins on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days)
To assess the effectiveness of the test products in terms of change in visual assessment of skin dryness
before usage of the test products on Day 01, after usage of the test products at T20 min on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days).
To assess the effectiveness of the test products in terms of change in visual assessment of skin smoothness
before usage of the test products on Day 01, after usage of the test products at T20 min on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days).
To assess the effectiveness of the test products in terms of change in visual assessment of skin roughness
before usage of the test products on Day 01, after usage of the test products at T20 min on Day 01, Day 08 (+2 Days), Day 30 (+2 Days) and Day 60 (+2 Days).
1\. Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical
Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical
Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical
Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical
NovoBliss Research Pvt.Ltd
Ahmedabad, Gujarat, 382481, India
Dr. Nayan K Patel
NovoBliss Research Pvt Ltd
84 participants (actual enrollment reported by the registry).
First Submitted
November 6, 2024
First Posted
November 7, 2024
Study Start
December 7, 2024
Actual (reported)Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical
Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed. Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
February 18, 2025
Actual (reported)Study Completion
February 18, 2025
Actual (reported)Last Updated
March 3, 2025
Record last verified: 2025-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: